Amgen’s Strong Quarter Highlights Healthcare Resilience Amid Tech and AI Selloff

Amgen’s quarterly outperformance highlights healthcare resilience

Amgen reports adjusted fourth-quarter earnings of $5.29 per share on $9.87 billion in revenue, handily topping LSEG estimates of $4.73 and $9.47 billion. The company’s results appear in midday market roundups as a notable bright spot amid broad technology weakness, reflecting sustained demand for its established medicines and near-term commercial stability. Amgen’s quarter features in CNBC’s rapid-fire coverage of earnings that are bucking the recent sector rotation.

The beat underscores a wider narrative in which large-cap biopharma firms act as defensive anchors while investors reassess high‑multiple tech and software names. Commentators on financial programs point to Amgen among health‑care blue chips that still offer value, citing steady fundamentals, diversified product portfolios and predictable cash flows as factors that differentiate the industry from more momentum-driven technology segments. The company’s performance feeds into discussions about portfolio allocation and the relative attractiveness of healthcare earnings in volatile markets.

Analysts and market commentators treat Amgen’s results as part of a sector-level story rather than an isolated move: reliable earnings delivery from established drugmakers is prompting some market participants to reweight toward health care and other traditional-cycle sectors. Amgen’s quarter reinforces this shift by demonstrating how regulatory‑ and product‑driven businesses can continue to deliver underlying revenue and earnings growth even as investors confront uncertainty around AI-driven demand dynamics in other parts of the market.

AI fears squeeze chips and enterprise software

The same market session sees steep declines in semiconductor and enterprise-software names after mixed guidance and heightened expectations. Advanced Micro Devices suffers a sharp selloff when forward guidance falls short of recent momentum-fueled estimates, and several large software firms register pullbacks as investors worry about AI-related demand and valuation resets.

Cramer presses case for diversification

CNBC’s Jim Cramer emphasizes that recent volatility highlights the need for diversified portfolios, noting that tech-only strategies are suffering and pointing to winners outside technology, including food, banks, industrials and health-care stalwarts such as Amgen. He discloses his Investing Club holdings and directs viewers to educational resources as market rotation accelerates.